Signal transduction induced by activated protein C: no role in protection against sepsis?

Trends in Molecular Medicine

Volumn 12, Issue 8, 2006, Pages 374-381

  Slofstra, Sjoukje H ^a   ten Cate, Hugo ^b   Spek, C Arnold ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MICROCIRCULATION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTICOAGULANTS; HUMANS; MODELS, BIOLOGICAL; PROTEIN C; SEPSIS; SIGNAL TRANSDUCTION;

EID: 33746629433     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.06.003     Document Type: Review

References (62)

1. Seligsohn U., et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N. Engl. J. Med. 310 (1984) 559-562
2. Marlar R.A., et al. Diagnosis and treatment of homozygous protein C deficiency. Report of the working party on homozygous protein C deficiency of the subcommittee on protein C and protein S, International committee on thrombosis and haemostasis. J. Pediatr. 114 (1989) 528-534
3. Broekmans A.W., et al. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N. Engl. J. Med. 309 (1983) 340-344
4. Griffin J.H., et al. Deficiency of protein C in congenital thrombotic disease. J. Clin. Invest. 68 (1981) 1370-1373
5. Taylor Jr. F.B., et al. A model for thrombin protection against endotoxin. Thromb. Res. 36 (1984) 177-185
6. Taylor Jr. F.B., et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78 (1991) 364-368
7. Bernard G.R., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344 (2001) 699-709
8. Stearns-Kurosawa D.J., et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10212-10216
9. Dahlback B., and Villoutreix B.O. Regulation of blood coagulation by the protein C anticoagulant pathway. Novel insights into structure-function relationships and molecular recognition. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1311-1320
10. Comp P.C., et al. Familial protein S deficiency is associated with recurrent thrombosis. J. Clin. Invest. 74 (1984) 2082-2088
11. Bertina R.M., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
12. Castoldi E., and Rosing J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr. Opin. Hematol. 11 (2004) 176-181
13. Lane D.A., et al. Inherited thrombophilia: Part 1. Thromb. Haemost. 76 (1996) 651-662
14. Esmon C.T., et al. Endothelial protein C receptor. Thromb. Haemost. 82 (1999) 251-258
15. Smith O.P., and White B. Infectious purpura fulminans: diagnosis and treatment. Br. J. Haematol. 104 (1999) 202-207
16. Faust S.N., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. 345 (2001) 408-416
17. Slofstra S.H., et al. Disseminated intravascular coagulation. Hematol. J. 4 (2003) 295-302
18. Ely E.W., et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit. Care Med. 31 (2003) 12-19
19. Polderman K.H., and Girbes A.R. Drug intervention trials in sepsis: divergent results. Lancet 363 (2004) 1721-1733
20. Laterre P.F., et al. Hospital mortality and resource use in subgroups of the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit. Care Med. 32 (2004) 2207-2218
21. Angus D.C., et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit. Care Med. 32 (2004) 2199-2206
22. Dellinger R.P., et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32 (2004) 858-873
23. Bernard G.R., et al. Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125 (2004) 2206-2216
24. Vincent J.L., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med. 33 (2005) 2266-2277
25. Abraham E., et al. Administration of drotrecogin alfa (Activated) in early stage severe sepsis (ADDRESS) study group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353 (2005) 1332-1341
26. Deans K.J., et al. The efficacy of drotrecogin alfa depends on severity of illness. Crit. Care Med. 32 (2004) 2347
27. Wiedermann C.J., and Kaneider N.C. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg. Med. 5 (2005) 7
28. Baillie J.K., and Murray G. Drotrecogin alfa (activated) in severe sepsis. N. Engl. J. Med. 354 (2006) 94-95
29. LaRosa S.P. Drotrecogin alfa (activated) in severe sepsis. N. Engl. J. Med. 354 (2006) 95
30. Friedrich J.O. Drotrecogin alfa (activated) in severe sepsis. N. Engl. J. Med. 354 (2006) 94-95
31. Yuksel M., et al. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb. Haemost. 88 (2002) 267-273
32. Joyce D.E., and Grinnell B.W. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB. Crit. Care Med. 30 (2002) S288-S293
33. Murakami K., et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. J. Physiol. 272 (1997) L197-L202
34. Hancock W.W., et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 60 (1995) 1525-1532
35. Joyce D.E., et al. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276 (2001) 11199-11203
36. Domotor E., et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 101 (2003) 4797-4801
37. Shibata M., et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103 (2001) 1799-1805
38. Cheng T., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9 (2003) 338-342
39. Mosnier L.O., and Griffin J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem. J. 373 (2003) 65-70
40. Zeng W., et al. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit. Care Med. 32 (2004) S302-S308
41. Feistritzer C., and Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105 (2005) 3178-3184
42. Finigan J.H., et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem. 280 (2005) 17286-17293
43. Riewald M., et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296 (2002) 1880-1882
44. Uchiba M., et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ. Res. 95 (2004) 34-41
45. De Backer D., et al. Microvascular blood flow is altered in patients with sepsis. Am. J. Respir. Crit. Care Med. 166 (2002) 98-104
46. Franscini N., et al. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 110 (2004) 2903-2909
47. Brueckmann M., et al. Recombinant human activated protein C upregulates cyclooxygenase-2 expression in endothelial cells via binding to endothelial cell protein C receptor and activation of protease-activated receptor-1. Thromb. Haemost. 93 (2005) 743-750
48. Kiefer P., et al. Hepatosplanchnic metabolic effects of the stable prostacyclin analogue iloprost in patients with septic shock. Intensive Care Med. 27 (2001) 1179-1186
49. De Backer. Is there a place for prostacyclin in the treatment of septic shock?. Intensive Care Med. 27 (2001) 1110-1112
50. Hooper W.C., et al. Activated protein C induction of MCP-1 in human endothelial cells: a possible role for endothelial cell nitric oxide synthase. Thromb. Res. 103 (2001) 209-219
51. Brueckmann M., et al. Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C. Thromb. Haemost. 89 (2003) 149-160
52. Riewald M., et al. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J. Endotoxin Res. 9 (2003) 317-321
53. Zisman D.A., et al. MCP-1 protects mice in lethal endotoxemia. J. Clin. Invest. 99 (1997) 2832-2836
54. Esmon C.T. Is APC activation of endothelial cell PAR1 important in severe sepsis? No. J. Thromb. Haemost. 3 (2005) 1910-1911
55. Ruf W. Is APC activation of endothelial cell PAR1 important in severe sepsis? Yes. J. Thromb. Haemost. 3 (2005) 1912-1914
56. Riewald M., and Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. 280 (2005) 19808-19814
57. Ludeman M.J., et al. PAR1 cleavage and signaling in response to activated protein C and thrombin. J. Biol. Chem. 280 (2005) 13122-13128
58. Dhainaut J.F., et al. Drotrecogin α (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb. Haemost. 90 (2003) 642-653
59. Derhaschnig U., et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102 (2003) 2093-2098
60. Kalil A.C., et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21 (2004) 222-229
61. Nick J.A., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104 (2004) 3878-3885
62. Sturn D.H., et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102 (2003) 1499-1505